Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 26% ± 9% | |
oligodendrocyte precursor cell | 12 studies | 39% ± 19% | |
oligodendrocyte | 11 studies | 29% ± 10% | |
microglial cell | 9 studies | 26% ± 9% | |
macrophage | 8 studies | 30% ± 11% | |
astrocyte | 7 studies | 28% ± 10% | |
epithelial cell | 6 studies | 28% ± 11% | |
dendritic cell | 6 studies | 20% ± 4% | |
myeloid cell | 5 studies | 27% ± 8% | |
adipocyte | 5 studies | 20% ± 4% | |
ciliated cell | 5 studies | 28% ± 9% | |
GABAergic neuron | 5 studies | 33% ± 15% | |
monocyte | 5 studies | 33% ± 8% | |
club cell | 5 studies | 25% ± 11% | |
type I pneumocyte | 5 studies | 34% ± 9% | |
type II pneumocyte | 5 studies | 27% ± 8% | |
non-classical monocyte | 4 studies | 22% ± 7% | |
glutamatergic neuron | 4 studies | 42% ± 14% | |
endothelial cell of lymphatic vessel | 4 studies | 23% ± 4% | |
fibroblast | 4 studies | 19% ± 4% | |
classical monocyte | 3 studies | 22% ± 3% | |
T cell | 3 studies | 22% ± 2% | |
alveolar macrophage | 3 studies | 35% ± 11% | |
chondrocyte | 3 studies | 64% ± 21% | |
respiratory goblet cell | 3 studies | 28% ± 12% | |
lymphocyte | 3 studies | 28% ± 6% | |
smooth muscle cell | 3 studies | 19% ± 1% | |
interneuron | 3 studies | 39% ± 19% | |
mucus secreting cell | 3 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3405.49 | 1445 / 1445 | 100% | 29.54 | 183 / 183 |
intestine | 100% | 3732.87 | 966 / 966 | 100% | 31.43 | 527 / 527 |
prostate | 100% | 3916.74 | 245 / 245 | 100% | 33.60 | 502 / 502 |
stomach | 100% | 3694.65 | 359 / 359 | 100% | 30.72 | 286 / 286 |
lung | 100% | 4495.35 | 577 / 578 | 100% | 25.50 | 1154 / 1155 |
pancreas | 100% | 3041.52 | 327 / 328 | 100% | 25.76 | 178 / 178 |
thymus | 100% | 4457.71 | 653 / 653 | 100% | 26.96 | 603 / 605 |
kidney | 100% | 5195.54 | 89 / 89 | 100% | 27.86 | 898 / 901 |
bladder | 100% | 3365.86 | 21 / 21 | 100% | 24.88 | 502 / 504 |
uterus | 100% | 4386.09 | 170 / 170 | 100% | 20.82 | 457 / 459 |
brain | 100% | 2946.40 | 2634 / 2642 | 100% | 32.03 | 704 / 705 |
skin | 100% | 4332.61 | 1809 / 1809 | 99% | 30.54 | 469 / 472 |
breast | 100% | 4325.34 | 459 / 459 | 99% | 26.66 | 1110 / 1118 |
ovary | 100% | 3886.47 | 180 / 180 | 99% | 17.63 | 424 / 430 |
adrenal gland | 100% | 5673.00 | 258 / 258 | 97% | 19.89 | 222 / 230 |
liver | 100% | 1739.77 | 225 / 226 | 97% | 14.07 | 393 / 406 |
adipose | 100% | 4368.49 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 12442.13 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 36.54 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.51 | 29 / 29 |
spleen | 100% | 5613.86 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 19.79 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.28 | 1 / 1 |
peripheral blood | 99% | 4822.82 | 922 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 2432.27 | 794 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 1762.89 | 831 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051224 | Biological process | negative regulation of protein transport |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0016567 | Biological process | protein ubiquitination |
GO_0042391 | Biological process | regulation of membrane potential |
GO_0032410 | Biological process | negative regulation of transporter activity |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0051865 | Biological process | protein autoubiquitination |
GO_1901016 | Biological process | regulation of potassium ion transmembrane transporter activity |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0034765 | Biological process | regulation of monoatomic ion transmembrane transport |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0036211 | Biological process | protein modification process |
GO_0070534 | Biological process | protein K63-linked ubiquitination |
GO_0006858 | Biological process | extracellular transport |
GO_0045746 | Biological process | negative regulation of Notch signaling pathway |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | WWP2 |
Protein name | NEDD4-like E3 ubiquitin-protein ligase WWP2 (EC 2.3.2.26) (Atrophin-1-interacting protein 2) (AIP2) (HECT-type E3 ubiquitin transferase WWP2) (WW domain-containing protein 2) WW domain containing E3 ubiquitin protein ligase 2 |
Synonyms | |
Description | FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and promotes it to proteasomal degradation; in embryonic stem cells (ESCs) the ubiquitination is proposed to regulate POU5F1 protein level. Ubiquitinates EGR2 and promotes it to proteasomal degradation; in T-cells the ubiquitination inhibits activation-induced cell death. Ubiquitinates SLC11A2; the ubiquitination is enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and promotes it to proteasomal degradation. . |
Accessions | ENST00000563659.5 H3BRX8 ENST00000359154.7 [O00308-1] ENST00000569620.5 O00308 ENST00000569174.5 [O00308-4] H3BS79 H3BPJ8 ENST00000561780.5 ENST00000356003.6 [O00308-2] ENST00000568684.1 [O00308-3] |